- Home
- EVOK vs RDHL Comparison
EVOK vs RDHL Comparison
Compare EVOK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVOK
- RDHL
- Stock Information
- Founded
- EVOK 2007
- RDHL 2009
- Country
- EVOK United States
- RDHL Israel
- Employees
- EVOK N/A
- RDHL N/A
- Industry
- EVOK Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- EVOK Health Care
- RDHL Health Care
- Exchange
- EVOK Nasdaq
- RDHL Nasdaq
- Market Cap
- EVOK 7.4M
- RDHL 8.2M
- IPO Year
- EVOK 2013
- RDHL N/A
- Fundamental
- Price
- EVOK $4.85
- RDHL $5.85
- Analyst Decision
- EVOK
- RDHL
- Analyst Count
- EVOK 0
- RDHL 0
- Target Price
- EVOK N/A
- RDHL N/A
- AVG Volume (30 Days)
- EVOK 10.1K
- RDHL 10.8K
- Earning Date
- EVOK 03-13-2025
- RDHL 08-29-2024
- Dividend Yield
- EVOK N/A
- RDHL N/A
- EPS Growth
- EVOK N/A
- RDHL N/A
- EPS
- EVOK N/A
- RDHL N/A
- Revenue
- EVOK $8,617,036.00
- RDHL $3,707,000.00
- Revenue This Year
- EVOK $97.35
- RDHL $224.90
- Revenue Next Year
- EVOK $99.52
- RDHL $82.69
- P/E Ratio
- EVOK N/A
- RDHL N/A
- Revenue Growth
- EVOK 100.35
- RDHL N/A
- 52 Week Low
- EVOK $3.54
- RDHL $5.41
- 52 Week High
- EVOK $12.32
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- EVOK 56.27
- RDHL 40.71
- Support Level
- EVOK $4.62
- RDHL $5.76
- Resistance Level
- EVOK $4.94
- RDHL $6.26
- Average True Range (ATR)
- EVOK 0.30
- RDHL 0.33
- MACD
- EVOK 0.06
- RDHL 0.01
- Stochastic Oscillator
- EVOK 59.28
- RDHL 20.17
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.